Eurofins Scientific stock slips below €72 and approaches its moving average
Eurofins Scientific declines during Monday's session, even as the CAC 40 resists slightly in positive territory. The stock falls back below €72, erasing part of the rebound that had propelled it near €74 last week. The macroeconomic backdrop remains laden with tensions, with anticipations of Federal Reserve rate hikes and persistent tensions around the Strait of Hormuz.
A decline that brings the stock back to its contact with its 20-day moving average
Eurofins Scientific loses 1.68% to €71.50 in session, standing out among the CAC 40's sharpest declines, in an index that nonetheless gains 0.32%. The stock finds itself practically at contact with its MA20, set at €71.41, with only a residual gap of 0.13%. This threshold thus becomes an immediate reference level: a further decline would take it below this average, which has not happened for several weeks.
The MA50, at €69.80, remains clearly below the current price (gap of 2.44%), as does the MA200 at €65.29 (gap of 9.51%), which preserves a positive structural configuration over longer horizons. The RSI at 59 remains in neutral-bullish territory, without signaling any notable excess in either direction. Over the week, the stock declines 1.19%, after having briefly touched €74 during Wednesday, September 3rd's session, a recent high that now constitutes the resistance level to monitor.
A half-year performance in recovery mode, with expectations on BioPharma in the second half
Behind today's correction, the fundamental momentum remains that traced during the publication of half-year results on July 23, 2026. The group had then indicated that profitability was close to its 2027 objective with more than one year's advance, and that the reduction in capital expenditure was contributing to significantly higher cash generation. Among the points of caution communicated on that occasion, organic revenue growth had not yet returned to normal pace in the first half of the year, and the BioPharma division remained affected by weak demand for its ancillary activities in North America.
The group nonetheless anticipated a turnaround in these activities in the second half of 2026, and expected the finalization of the acquisition of Element Materials Technology (over $150 million in annual revenues) by the end of the fourth quarter. The stock nonetheless displays a gain of 10.14% over three months and 12% over one year, which testifies to a positive underlying trend, even if the resistance at €74.08 has not yet been breached.
